By Wokandpix. CC0 Creative Commons.

Good week for the healthcare sector, with Eli Lilly and AstraZeneca posting positive earnings and Takeda reportedly moving closer to acquiring Shire. Concerns over antimicrobial resistance continue but an OECD report states that to fight “superbugs” globally would cost US$2 per person.

In local news, representatives from the Minister of Health stated that the sector has a not-enough–women problem and that one out of every four Mexicans will face a mental disease in their lives. Baja California’s medical devices sector keeps growing and a Spanish hospital allied with a local software development to create an Innovation in Healthcare Center.

Mexico Health Review spoke to Erik Musalem, General Manager of Gilead Sciences Mexico, about the company’s portfolio and strategies to address HIV and hepatitis.

Now jump into last week’s highlights:

 

National

Doctors from the Ministry of Health explain that 25 percent of Mexicans face a mental disease during their lives but only 3 percent receive medical treatment.

Spanish Clinical Hospital San Carlos de Madrid allied with local company Nubaj IT & Consulting to launch the Innovation in Healthcare Center Thinnkup in Mexico City.

The Minister of Health identified a  gender gap in the healthcare sector, which still has a limited presence of women.

Baja California’s medical devices sector reported an expected 10 percent growth in 2018. The state now has 79 medical device companies employing 65,000 workers.

 

International

Stopping “superbug” infections globally could cost only US$2 per person, said the OECD referring to the growing antimicrobial resistance problem.

AstraZeneca reported 9 percent growth in sales during 3Q18 due to strong demand for its new medicines.

Takeda continues to move forward in its takeover of Shire. The US$62-billion bid, which would be the largest in history for a Japanese company, may win EU antitrust approval according to insiders.

Eli Lilly reports stronger-than-expected earnings for 3Q18. The pharmaceutical is removing its Beta-secretase (BASE) program for an Alzheimer’s treatment from its pipeline following a series of setbacks that have placed the theory behind it in doubt.

Share →

Leave a Reply

Your email address will not be published. Required fields are marked *